Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572825 · ClinicalTrials.gov registry record · Phase 1
Assessing the Safety and Tolerability of NMN in DHDDS-CDG
A Phase 1 study, sponsored by Eva Morava-Kozicz.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07572825 is a Phase 1 study that is actively recruiting participants, run by Eva Morava-Kozicz. The registered enrollment target is 8 participants.
The verdict
NCT07572825, a Phase 1 study, is actively recruiting participants, sponsored by Eva Morava-Kozicz.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Interventions
- DRUG Nicotinamide Mononucleotide (NMN) Nucleosidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-05-08 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07572825
The ClinicalTrials.gov registry entry for NCT07572825 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eva Morava-Kozicz, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nicotinamide Mononucleotide (NMN) Nucleosidase is the first listed.
NCT07572825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07572825 about?
NCT07572825 is a clinical study titled "Assessing the Safety and Tolerability of NMN in DHDDS-CDG". The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow...
What is the current status of trial NCT07572825?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-05-08. Estimated completion is 2027-08-01.
What interventions are being tested in trial NCT07572825?
The interventions under investigation include: Nicotinamide Mononucleotide (NMN) Nucleosidase (DRUG).
Who is sponsoring clinical trial NCT07572825?
This trial is sponsored by Eva Morava-Kozicz, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.